Reflections on COPD Comorbidities.

Zhenming He,Yue Wang,Lin Shan,Yan Mou,Yunhuan Liu,Guanhua Ma,Yanxu Wu,Huili Zhu,Jeffrey L Curtis,Shilei Cui,Haiyan Ge

DOI: https://doi.org/10.1097/cm9.0000000000003131

IF: 6.133

2024-01-01

Chinese Medical Journal

Abstract:To the Editor: Chronic obstructive pulmonary disease (COPD) is a common disease among the elderly, affecting over one-third of the elderly population worldwide. The progressive decline in lung function characteristic of COPD significantly impacts the quality of life and employability of affected individuals, resulting in a substantial direct and indirect socioeconomic burden. COPD frequently has comorbidities involving other organ systems. Virtually all elderly COPD patients present with one or more comorbid conditions, collectively exacerbating health and economic burdens. While viral and bacterial infections remain the most common triggers for COPD exacerbations (ECOPD), other factors such as comorbid heart failure, coronary heart disease, pulmonary embolism, and panic attacks have also been identified as additional risk factors. As the COPD comorbidity is getting more concern in the long-term management of COPD, comprehensive assessment and treatment strategies become essential to alleviate the disease burden and enhance patients' quality of life. In this study, we explored clinical indicators for predicting ECOPD risk, as well as the potential benefits of applying the Internet of Things (IoT) concept to COPD management. Combining IoT platforms with indices of ECOPD risk may optimize management of comorbidities in elderly COPD patients, providing a more holistic and effective approach to COPD management. COPD is characterized by airflow obstruction, often accompanied by chronic bronchitis and/or emphysema. This condition can progress to cor pulmonale and respiratory failure. COPD primarily results from prolonged exposure to cigarette smoke or other harmful gases and particles, leading to various complications like skeletal muscle dysfunction, respiratory failure, and reduced peripheral blood flow. The term of "comorbidity" traditionally refers to "additional clinical conditions that either coexist with or may develop during the clinical course of a patient already diagnosed with the index disease under study." In China, most elderly COPD patients have comorbidities, with around 52.8% experiencing one or two additional clinical conditions. Notably, over half of them suffer from cardiovascular system diseases (CVD). In patients with both COPD and CVD, the interactions among the respiratory, cardiac, and vascular systems are complex. The progression of COPD may lead to adverse cardiovascular events such as right heart failure. Drugs for COPD treatment such as beta agonists may lead to rapid arrhythmias. In order to control the disease, some patients need to inhale high doses of corticosteroids, which increases the risk of diabetes related hospitalization.[1] Therefore, any single treatment for COPD or comorbidities is not enough to cover all aspects of the disease. Globally, COPD affects approximately 10.3% of individuals aged 30–79 years, equating to approximately 391.9 million people.[2] The reported prevalence of COPD varies across different regions of China, ranging from 5% to 13%. COPD comorbidity is associated with unfavorable outcomes, including an increased risk of exacerbations. For every additional comorbidity, the risk of mortality rises by 36%.[3] It is important to note that international guidelines for COPD management often focus on isolated lung impairment rather than considering comorbidities systematically during diagnosis and treatment decisions. Therefore, there is a clear need for a specific system to address the management of COPD comorbidities. Numerous biomarkers have been extensively researched to predict clinically relevant outcomes in COPD, including mortality rates, exacerbations, and hospitalizations. One such biomarker is C-reactive protein (CRP), which is significantly associated with mortality in COPD patients. Another valuable prognostic biomarker is the elevated neutrophil cluster of differentiation (CD)64 index (nCD64), which reliably predicts both short-term and long-term mortality in patients experiencing exacerbations. Elvated values of red blood cell distribution width (RDW) are also linked to an increased risk of early readmission and mortality among exacerbating patients. These elevated RDW values may suggest underlying chronic hypoxemia, inflammation, or oxidative stress. Recent studies have indicated that mucin 5AC (MUC5AC) could be a novel biomarker for assessing COPD prognosis and predicting the efficacy of therapeutic interventions. Additionally, some earlier research suggested that lipoprotein-associated phospholipase A2 (Lp-PLA2) could be suitable for assessing exercise tolerance in clinical practice. Furthermore, chemokine (C-X-C motif) ligand 10 (CXCL10) has emerged as a leading biomarker for detecting virally induced ECOPDs, and granulocyte colony-stimulating factor (G-CSF) has implicated in the pathogenesis of COPD and its comorbidities. Moreover, our previous research has identified several hemogram indexes, including the platelet–lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), the body mass index, airflow obstruction, dyspnea, and exacerbations index (BODEx) as being associated with ECOPD. These indexes may offer valuable insights into COPD management and exacerbation risk assessment. Overall, these biomarkers represent a potentially valuable avenue for enhancing COPD diagnosis, prognosis, and treatment, although further research and validation are needed to definitively establish their clinical utility. Various methods have been explored in previous studies to assess comorbidity in the context of COPD. The Charlson Comorbidity Index (CCI) was empirically developed, drawing upon one-year mortality data from an inception cohort study involving 604 participants at New York Hospital in 1984. In 1998, the Elixhauser comorbidity measure, which incorporated the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) manual, was introduced to overcome the limitations of earlier comorbidity research. Additional comorbidity indices are also available, including the Comorbidity Test (COTE) and the Dyspnoea, Eosinopenia, Consolidation, Acidaemia, and Atrial Fibrillation (DECAF) score. These indices vary in their predictive capability and applicability. Given that COPD is a complex, multifaceted disease with multiple phenotypes and sub-phenotypes, the choice of one index over another should primarily hinge on the specific outcome of interest. Our three-year observational study of the Shanghai COPD Investigation on Comorbidity Program (SCICP) cohort revealed a strong association between ECOPD and a combination of the BODEx index and four comorbid conditions: hypertension, allergic rhinitis, angina, and anxiety. Notably, hypertension, angina, and anxiety emerged as independent risk factors for ECOPD. This research integrated biological markers and comorbidities to predict COPD outcomes. In recent years, a precision medicine approach has emerged as a viable strategy for managing COPD. Precision medicine involves tailoring treatments to individual patients based on their unique genetic, biomarker, phenotypic, or psychosocial characteristics, which distinguish them from others with similar clinical presentations. This approach is referred to as "precision" because it does not create bespoke drugs or medical devices for each patient but rather categorizes individuals based on specific disease characteristics, including their responses to particular treatments.[4] The concept of "IoT medicine" coined by Prof. Chunxue Bai of Zhongshan Hospital, Fudan University in China, refers to the extend the Internet's data transfer capabilities to physical objects through various wireless devices. This enhances the flexibility of data collection and disease management, providing a platform for implementing precision medicine.[5] A COPD management system based on the IoT was established and designed for the collective management of COPD patients with comorbidities. This comprehensive system encompasses data entry, parameter configuration, score calculation, and warning functions. These pathways include pre-diagnosis, triage, expert, and follow-up teams. Building upon this comorbidity system, personalized treatment pathways for COPD patients can be implemented. To elaborate further, the first step is collecting baseline information and conducting comorbidity assessments using the aforementioned evaluation system and related devices. Exacerbated patients with common or specific comorbidities may be recommended for hospitalization, with their data shared for multidisciplinary consultations. Data from nonhospitalized patients in the triage phase are also entered into the management platform, with disease monitoring by the follow-up team [Figure 1]. This system will undergo validation in multiple medical centers to ensure its effectiveness and reliability.Figure 1: IoT-based COPD management system with comorbidity assessment (A) and personalized pathways (B). COPD: Chronic obstructive pulmonary disease; IoT: Internet of things.In this article, we discuss the current state and future possibilities of managing comorbidities in elderly COPD patients in China. COPD patients often share common risk factors that lead to prevalent comorbidities, and further exploration of additional risk factors appears to be a more effective practice. Precision medicine has further enhanced COPD management, and a health-management platform based on the IoT was established. This platform combines COPD and comorbidity management with individualized diagnosis and treatment pathways. Exploring long-term effective health-management approaches for COPD patients may potentially transform the current model of diagnosis and management: the diagnosis and treatment of the same patient by different specialists in different hospitals could gradually evolve into a standardized and integrated medical model. Funding This work was supported by grants from National Key R&D Program of China (Nos. 2020YFC2009000 and 2020YFC2009001), Scientific Research Project of Shanghai Science and Technology Commission (Nos. 22Y11901200 and 21140902500), Scientific Research Project of Shanghai Municipal Health Commission (Nos. 2022XD030 and 202140036), Shanghai Municipal Key Clinical Specialty (No. shslczdzk02801), Investigator-initiated clinical trials Foundation of Huadong Hospital (Nos. HDLC2022018, ZDXK2216, ZDZB2226, and JYRC202209), and Shanghai Health System Young Talent Fund Project Hengjie-Special Support Program (No. 2022-020). Conflicts of interest None.